Despite the disappointing result of the recently released data of clinical trials, especially extensively-concerned phase III trials with immune checkpoint inhibitors PD-1/PD-L1, CTLA-4, CAR-T therapy and viral therapy, tumor vaccine has shown its potential with the new understanding of TAAs and immunosuppressive mechanism of tumor microenvironment. This evidence concerns the gene CTLA4 and neoplasm.